Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter (O) November 9, 2016

Crystal structure of (E)-2-({4-hydroxy-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]phenyl} methylidene)-1-indanone, C23H26N2O3

  • Mehtap Tugrak , Abdullah Aydin EMAIL logo , Halise Inci Gul , Ertan Sahin and Mehmet Akkurt

Abstract

C23H26N2O3, triclinic, P1̅ (No. 2), a = 10.6646(19) Å, b = 10.7784(17) Å, c = 11.150(2) Å, α = 67.787(7)°, β = 64.309(7)°, γ = 64.271(7)°, V = 1011.6(3) Å3, Z = 2, Rgt(F) = 0.0502, wRref(F2) = 0.1481, T = 293 K.

CCDC no.:: 1444431

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Bronze blocks
Size:0.10 × 0.08 × 0.06 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.8 cm−1
Diffractometer, scan mode:Rigaku R-axis, φ and ω
2θmax, completeness:57°, >99%
N(hkl)measured, N(hkl)unique, Rint:44547, 5072, 0.053
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3072
N(param)refined:256
Programs:Rigaku [9], SHELX [10], ORTEP [11], Platon [12]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.35602(16)−0.07674(14)0.90803(13)0.0767(5)
O20.72921(12)0.47509(12)0.36865(10)0.0525(4)
O30.85324(13)0.48429(13)0.52280(11)0.0572(4)
N10.83849(13)0.43732(14)0.78758(12)0.0467(4)
N20.78787(15)0.63576(15)0.93081(13)0.0551(5)
C10.39093(17)0.16858(16)0.57632(15)0.0462(5)
C20.27926(17)0.10499(16)0.59942(15)0.0461(5)
C30.2007(2)0.1327(2)0.51526(18)0.0639(7)
C40.1036(2)0.0617(2)0.5565(2)0.0750(8)
C50.0817(2)−0.0360(2)0.6806(2)0.0729(8)
C60.1574(2)−0.06358(18)0.76599(19)0.0611(6)
C70.25665(17)0.00772(15)0.72369(16)0.0467(5)
C80.35036(18)−0.00220(16)0.79465(16)0.0507(5)
C90.43529(16)0.09651(15)0.70393(14)0.0440(4)
C100.52874(17)0.11134(16)0.74342(15)0.0474(5)
C110.61842(16)0.20355(16)0.67922(15)0.0440(4)
C120.68997(17)0.20876(16)0.75507(15)0.0470(5)
C130.77119(17)0.29910(16)0.70493(15)0.0462(5)
C140.77934(16)0.39021(16)0.57557(15)0.0436(5)
C150.71168(16)0.38373(16)0.49535(14)0.0427(4)
C160.63320(16)0.29172(16)0.54642(14)0.0437(5)
C170.67428(19)0.46372(18)0.27885(16)0.0547(5)
C180.85842(19)0.29538(18)0.78309(17)0.0533(6)
C190.95267(17)0.43322(18)0.83025(17)0.0516(5)
C200.93170(18)0.57806(18)0.83613(16)0.0537(5)
C210.67330(18)0.64073(19)0.88984(18)0.0603(6)
C220.69325(18)0.49664(19)0.88230(17)0.0569(6)
C230.7679(3)0.7755(2)0.9382(2)0.0790(8)
H1A0.348000.270300.566600.0550*
H1B0.474700.148700.495300.0550*
H30.213700.198800.431800.0770*
H3O0.866500.495700.584600.0860*
H40.051500.079700.499900.0900*
H50.01550−0.083200.706400.0880*
H60.14250−0.128400.850100.0730*
H100.538000.051900.827200.0570*
H120.683000.149700.842200.0560*
H160.589200.287600.492600.0520*
H17A0.716500.368300.267700.0820*
H17B0.700100.527300.191400.0820*
H17C0.569200.487900.316800.0820*
H18A0.828500.240000.875900.0640*
H18B0.961900.248700.740500.0640*
H19A1.048700.397200.766100.0620*
H19B0.949000.369400.919800.0620*
H20A1.007800.572600.865400.0640*
H20B0.940800.640600.745500.0640*
H21A0.675600.705700.801000.0720*
H21B0.578000.676000.955200.0720*
H22A0.682800.433600.972700.0680*
H22B0.617400.503800.851800.0680*
H23A0.776300.838300.849000.1190*
H23B0.841900.768700.969600.1190*
H23C0.672200.811501.000800.1190*

Source of material

The mixture of 2-(4-hydroxy-3-methoxybenzylidene)-2,3-dihydroinden-1-one (21 mmol), paraformaldehyde (25 mmol) and N-methyl piperazine (21 mmol) was heated in 15 mL of acetonitrile (393 K) for 10 min. The product was purified by crystallization firstly from methanol-hexane and then from chloroform-hexane. [Yield: 40%, mp.: 471–473 K]. 1H NMR (400 MHz, CDCl3, p.p.m.) δ 7.87 (d, 1H, Ar—H, J = 7.7 Hz, indanone), 7.60–7.53 (m, 3H, Ar—H, indanone, vinylic-H), 7.40 (bt, 1H, Ar—H, J = 7.1 Hz, indanone), 6.97 (s, 1H, Ar—H), 7.11 (s, 1H, Ar—H), 3.98 (s, 2H, 3-CH2, indanone), 3.94 (s, 3H, –OCH3), 3.79 (s, 2H, Ar—CH2N–), 3.00–2.30 (m, 8H, CH2-piperazine), 2.29 (s, 3H, –N—CH3); 13C NMR (100 MHz, CDCl3, p.p.m.) δ 194.4, 149.8, 149.5, 148.4, 138.5, 134.6, 134.5, 132.0, 127.8, 126.7, 126.3, 124.5, 124.4, 121.7, 113.7, 61.3, 56.2, 55.0, 52.7, 46.1, 32.6; Mass spectrum: 379.20 (M+ + 1); HRMS (ESI-MS) Calc.: 379.2022 for C23H27N2O3 [M + H]+, Found: 379.2025 [1].

Experimental details

H atom were placed in calculated positions with O—H = 0.82 Å, C—H = 0.93–0.96 Å, and refined using a riding model with Uiso(H) = 1.2Ueq(C) for the aromatic and methylene H atoms and Uiso(H) = 1.5Ueq(C,O) for the methyl and hydroxyl H atoms.

Discussion

Mannich bases have several biological activities such as antimicrobial [2], antifungal [3], anticonvulsant [4], anti-inflammatory [5], and cytotoxic/anticancer [6, 7] activities. The title Mannich base, 2-[4-hydroxy-5-methoxy-3-(4-methyl-piperazin-1-ylmethyl)-benzylidene]-indan-1-one (cf. the figure) can be concluded from the figure was synthesized starting from 2-(4-hydroxy-3-methoxybenzylidene)-indan-1-one, and was tested as inhibitors of the zinc metalloenzyme cytosolic human carbonic anhydrase (hCA I, and II) isoforms. The title compound is a strong hCA I (Ki: 484.02 ± 30.30 nM) and II inhibitor (Ki: 526.30 ± 112.9 nM).

In the title compound, the piperazine ring (N1/N2/C19—C22) adopts a chair conformation with the puckering parameters [8] of QT = 0.5697(19) Å, θ = 0.0(2)° and φ = 82(12)°, respectively. The 2,3-dihydro-1H-indene ring system (C1—C9) is essentially planar [the puckering parameters are Q(2) = 0.007(2) Å and φ(2) = 20(16)°] and its mean plane makes a dihedral angle of 9.27(7)° with the central benzene ring (C11—C16). The intramolecular O3—H3O⋯N1 hydrogen bonds stabilizes the molecular conformation of the title compound. In the crystal, molecules are linked by weak C—H⋯O, C—H⋯N and C—H⋯π interactions.

Acknowledgements

The authors are indebted to the Department of Chemistry, Atatürk University, Erzurum, Turkey, for use of the X-ray diffractometer purchased under grant No.2003/219 of the University Research Fund.

References

1 Tugrak, M.; Yamali, C.; Sakagami, H.; Gul, H. I.: Synthesis of mono Mannich bases of 2-(4-hydroxybenzylidene)-2,3-dihydroinden-1-one and evaluation of their cytotoxicities. J. Enzyme Inhib. Med. Chem. 6 (2015) 1–6.10.3109/14756366.2015.1070263Search in Google Scholar PubMed

2 Gul, H. I.; Sahin, F.; Gul, M.; Ozturk, S.; Yerdelen, K. O.: Evaluation of antimicrobial activities of several Mannich bases and their derivatives. Arch. Pharm. 338 (2005) 335–338.10.1002/ardp.200400962Search in Google Scholar PubMed

3 Mete, E.; Gul, H. I.; Bilginer, S.; Algul, O.; Topaloglu, M. E.; Gulluce, M.; Kazaz, C.: Synthesis and antifungal evaluation of 1-aryl-2-dimethyl-aminomethyl-2-propen-1-one hydrochlorides. Molecules 16 (2011) 4660–4671.10.3390/molecules16064660Search in Google Scholar PubMed PubMed Central

4 Gul, H. I.; Calls, U.; Ozturk, Z.; Tutar, E.; Calikiran, L.: Evaluation of anticonvulsant activities of bis(3-aryl-3-oxo-propyl) ethylamine hydrochlorides and 4-aryl-3-arylcarbonyl-1-ethyl-4-piperidinol hydrochlorides. Arzneimittelforschung 57 (2007) 133–136.10.1055/s-0031-1296595Search in Google Scholar PubMed

5 Suleyman, H.; Gul, H. I.; Gul, M.; Alkan, M.; Gocer, F.: Anti-inflammatory activity of bis(3-aryl-3-oxo-propyl)methylamine hydrochloride in Rat. Biol. Pharm. Bull. 30 (2007) 63–67.10.1248/bpb.30.63Search in Google Scholar PubMed

6 Bilginer, S.; Gul, H. I.; Mete, E.; Das, U.; Sakagami, H.; Umemura, N.; Dimmock, J. R.: 1-(3-Aminomethyl-4-hydroxyphenyl)-3-pyridinyl-2-propen-1-ones: a novel group of tumour-selective cytotoxins. J. Enzyme Inhib. Med. Chem. 28 (2013) 974–980.10.3109/14756366.2012.700927Search in Google Scholar PubMed

7 Yerdelen, K. O.; Gul, H. I.; Sakagami, H.; Umemura, N.; Sukuroglu, M.: Synthesis and cytotoxic activities of a curcumin analogue and its bis-Mannich derivatives. Lett. Drug. Des. Discov. 12 (2015) 643–649.10.2174/1570180812666150213225134Search in Google Scholar

8 Cremer, D.; Pople, J. A.: General definition of ring puckering coordinates. J. Am. Chem. Soc. 97 (1975) 1354–1358.10.1021/ja00839a011Search in Google Scholar

9 Rigaku/MSC: CrystalClear. Rigaku/MSC, The Woodlands, Texas, USA, 2005.Search in Google Scholar

10 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed

11 Farrugia, L. J.: ORTEP-3 for Windows a version of ORTEP III with a Graphical User Interface (GUI). J. Appl. Crystallogr. 45 (2012) 849–854.10.1107/S0021889897003117Search in Google Scholar

12 Spek, A. L: Structure validation in chemical crystallography. J. Appl. Cryst. 36 (2003) 7–13.10.1107/S090744490804362XSearch in Google Scholar PubMed PubMed Central

Received: 2016-5-31
Accepted: 2016-10-14
Published Online: 2016-11-9
Published in Print: 2017-1-1

©2016 Mehtap Tugrak et al., published by De Gruyter.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 31.5.2024 from https://www.degruyter.com/document/doi/10.1515/ncrs-2016-0176/html
Scroll to top button